
Retatrutide
Triple-receptor compound studied for appetite, blood-sugar, and body-weight regulation.
For Research Use Only
Sold strictly for laboratory research. Not for human or veterinary use, ingestion, or clinical/diagnostic application.
The lower price is applied automatically once your cart holds 5 or more of this vial.
Bacteriostatic water included
About this peptide
Retatrutide is an investigational triple-receptor agonist peptide. It acts on GLP-1, GIP, and glucagon receptors, three signalling systems involved in appetite, blood-sugar control, and how the body uses stored energy. Researchers study this combined action in metabolic and body-weight regulation models.
Why researchers reach for Retatrutide
Triple-receptor pharmacology
Simultaneously engages GLP-1, GIP and glucagon receptors.
Adiposity models
Referenced across rodent DIO and NHP obesity studies.
Glucose regulation
Preclinical data on insulin secretion and hepatic glucose output.
Key features
- ≥99% HPLC purity
- Fatty-acid conjugated backbone
- Mass-spec verified
- Cold-chain dispatch
How it works
Incretin signaling
Amplifies glucose-dependent insulin release via GLP-1 and GIP receptors.
Glucagon-mediated energy expenditure
Adds glucagon receptor engagement for thermogenic tone in animal models.
Extended half-life
Albumin-binding fatty acid moiety supports weekly dosing paradigms in research.
Research dosage guidelines
Reference ranges only — reproduced from published preclinical literature. Not a recommendation for human use.
| Range | Reported dose | Note |
|---|---|---|
| Typical reconstitution | 2 mL bacteriostatic water | Yields 15 mg/mL (15 000 mcg/mL) |
| Reported research range | 2–12 mg/week (titrated) | Reference only |
Tracking this compound? Registered researchers can log active Retatrutide protocols in their private Research Log.
Timing in research protocols
Once weekly on a consistent day; time of day is pharmacologically immaterial.
- The phase 2 randomised trial (Jastreboff et al., NEJM 2023) used once-weekly subcutaneous dosing for 48 weeks, with dose escalation and a 24-week primary endpoint.
- The half-life for this receptor-agonist class is roughly 6 days, so plasma levels do not track the clock.
- The protocol did not specify or test time of day or fasting state; consistency of the weekly dosing day is the operative variable.
- Published study duration: up to 48 weeks with stepwise escalation.
Drawn from published research protocols and pharmacology literature. Reference information for laboratory research only — not an instruction or guidance for use.
Technical specifications
- Class
- GLP-1 / GIP / glucagon triple receptor agonist
- Peptide structure
- 39-residue Aib-substituted peptide, C20 fatty-acid conjugated
- Molecular weight
- ~4731 g/mol
- Purity
- ≥99% (HPLC)
- Form
- Lyophilized powder
- Vial size
- 30 mg
- Storage (lyophilised vial)
- Cool, dry and protected from light
- Storage (after reconstitution)
- 2–8°C
Published research
Peer-reviewed literature on Retatrutide. Links open in a new tab.
Research use notice
Sold for in vitro laboratory research only. Not for human or veterinary use, diagnosis, or therapy.
